Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Erlotinib + Ficlatuzumab||Phase I||Actionable||In a Phase I trial, Ficlatuzumab (AV-299) in combination with Tarceva (erlotinib) was shown to be safe in treating patients with advanced solid tumors (PMID: 23493885, J Clin Oncol. 2010;28(Suppl) Abstract 2525).||23493885 detail...|
|PubMed Id||Reference Title||Details|
|(23493885)||Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer.||Full reference...|
|Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors.||Full reference...|